Special Drug Use-results Survey of Targretin Capsules combined with photo(chemo)therapy

Special Drug Use-results Survey of Targretin Capsules 75mg combined with photo(chemo)therapy for cutaneous T-cell lymphoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031210625

Enrollment

Registered

2022-02-23

Start date

2022-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous T-cell lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Cases in which UV therapy is being performed and the combined use of bexarotene and UV therapy is started during the registration period. However, if bexarotene has been used, cases that have not been administered for more than 4 weeks since the last administration (2) Cases registered for the first time in this survey (3) Patients who have been treated with UV therapy at a standard frequency (at least once a week) for about one month before the start of concomitant use with bexarotene, and the status of the treatment can be confirmed. (4) Cases in which the consent of the patient was obtained

Exclusion criteria

Exclusion criteria: adult T-cell leukemia/lymphoma

Design outcomes

Primary

Measure	Time frame
Incidence of photosensitivity and similar skin adverse events and their 95% confidence intervals	—

Secondary

Measure	Time frame
The incidence of adverse events by System Organ Class(SOC) and Preferred Term(PT) using MedDRA / J and its 95% confidence interval Response rate (CR + PR) and its confidence interval based on the best overall effect of mSWAT.	—

Contacts

Public Contactdepartment pharmacovigilance

Minophagen Pharmaceutical Co., Ltd.

gvp@minophagen.co.jp+81-3-5909-2323

Outcome results